Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-08-04
2009-12-15
Lewis, Patrick T (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S045000, C514S048000, C514S049000, C514S050000, C514S051000, C536S027100, C536S027130, C536S028100
Reexamination Certificate
active
07632821
ABSTRACT:
The present invention provides ribonucleoside 2′,3′-cyclic acetals of structural formula I which are precursors or prodrugs of inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors of inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors or prodrugs of inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors or prodrugs of inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such ribonucleoside 2′,3′-cyclic acetals alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the ribonucleoside 2′,3′-cyclic acetals of the present invention.
REFERENCES:
patent: 5134154 (1992-07-01), Freedman et al.
Bartenschlager, R. “Candidate Targets for Hepatitis C Virus-Specific Antiviral Therapy”, Intervirology, 1997, vol. 40, pp. 378-393.
Brass, V. et al. “Recent developments in target identification against hepatitis C virus”, Expert Opin. Ther. Targets, 2004, vol. 8, pp. 295-307.
Crabb, C. “Hard-Won Advances Spark Excitement About Hepatitis C”, Science, 2001, vol. 294, pp. 506-507.
Dymock, B. “Emerging therapies for hepatitis C virus infection”, Emerging Drugs, 2001, vol. 6, pp. 13-42.
Dymock, B. et al. “Novel approaches to the treatment of hepatitis C virus infection”, Antiviral Chemistry & Chemotherapy, 2000, vol. 11, pp. 79-96.
Eldrup, A. et al. “Structure-Activity Relationship of Purine Ribonucleosides for Inhibition of Hepatitis C Virus RNA-Dependent RNA Polymerase”, J. Med. Chem., 2004, vol. 47, pp. 2283-2295.
Hampton A. et al. “Nucleotides. IV. Conversion of Ribonucleosides to New 2′,3′-Ketal Derivatives”, Journal of the American Chemical Society, 1965, vol. 87, pp. 5481-5487.
Hoffmann, P. et al. “Recent patents on experimental therapy for hepatitis C virus infection (1999-2002)”, Expert. Opin. Ther. Patents, 2003, vol. 13, pp. 1707-1723.
Ishi, K. et al. “Expression of Hepatitis C Virus NS5B Protein: Characterization if Its RNA Polymerase Activity and RNA Binding”, Hepatology, 1999, vol. 29, pp. 1227-1235.
Lauer, G. et al. “Hepatitis C Virus Infection”, New England Journal of Medicine, 2001, vol. 345, pp. 41-52.
Lohmann, V. et al. “Biochemical and Kinetic Analyses of NS5B RNA-Dependent RNA Polymerase of the Hepatitis C Virus”, Virology, 1998, vol. 249, pp. 108-118.
Moradpour, D. et al. “Current and evolving therapies for hepatitis C”, European Journal of Gastroenterology & Hepatology, 1999, vol. 11, pp. 1199-1202.
Rosen, H. et al. “Hepatitis C virus: current understanding and prospects for future therapies”, Molecular Medicine Today, 1999, vol. 5, pp. 393-399.
Walker, M. et al. “Promising candidates for the treatment of chronic hepatitis C”, Expert Opin. Investig. Drugs, 2003, vol. 12, pp. 1269-1280.
Butora Gabor
Koeplinger Kenneth Alan
MacCoss Malcolm
McMasters Daniel R.
Olsen David B.
Durette Philippe L.
Heber Sheldon O.
Lewis Patrick T
Merck & Co. , Inc.
Walton Kenneth R.
LandOfFree
Ribonucleoside cyclic acetal derivatives for the treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ribonucleoside cyclic acetal derivatives for the treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ribonucleoside cyclic acetal derivatives for the treatment... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4061990